BIOMARIN PHARMACEUTICAL INC Debt Securities, Available-for-sale, Current
BIOMARIN PHARMACEUTICAL INC (BMRN) had Debt Securities, Available-for-sale, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Current $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Current $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Current $248.93M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $227.73M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 |
| 2025-12-31 | $248.93M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $227.73M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $218.31M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $223.53M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $194.86M 10-K · filed 2026-02-26 |
| 2024-09-30 | $255.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $252.20M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $299.58M 10-Q · filed 2024-04-26 |
| 2023-12-31 | $318.68M 10-K · filed 2025-02-24 |
| 2023-09-30 | $340.43M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $476.58M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $572.02M 10-Q · filed 2023-04-28 |
| 2022-12-31 | $567.01M 10-K · filed 2024-02-26 |
| 2022-09-30 | $512.25M 10-Q · filed 2022-10-28 |
| 2022-06-30 | $489.94M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $450.80M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $426.60M 10-K · filed 2023-02-27 |
| 2021-09-30 | $462.33M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $481.86M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $420.18M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $416.23M 10-K · filed 2022-02-25 |
| 2020-09-30 | $490.00M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $561.47M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $381.76M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $316.36M 10-K · filed 2021-02-26 |
| 2019-09-30 | $297.57M 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $423.53M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $530.49M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $590.33M 10-K · filed 2020-02-27 |
| 2018-09-30 | $561.19M 10-Q · filed 2018-10-26 |
| 2017-12-31 | $797.94M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |